Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

418700

registered interest
date	14/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Dental Services: Children
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will take steps to encourage orthodontists to offer NHS appointments to children outside school hours.
tabling member constituency	Twickenham
tabling member printed	Dr Tania Mathias
uin	10177
answer	answer is ministerial correction date of answer 17/09/2015 answer text <p>NHS England contracts for orthodontic services at a local level taking account of the local oral health needs. Therefore opening hours are a matter for agreement between local commissioners and providers.</p><p> </p> answering member constituency North East Bedfordshire answering member printed Alistair Burt question first answered 17/09/2015 10:09:04 answering member 1201 label Biography information for Alistair Burt
tabling member	4404 label Biography information for Dr Tania Mathias

418701

registered interest
date	14/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pregnancy: Screening
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment the NHS has made of the potential benefits and disadvantages of the use of Doppler scans in preventing stillbirths.
tabling member constituency	Twickenham
tabling member printed	Dr Tania Mathias
uin	10175
answer	answer is ministerial correction date of answer 17/09/2015 answer text <p>The UK National Screening Committee (UK NSC) which advises Ministers and the National Health Service in all four countries about all aspects of screening is currently looking at the evidence for a variety of tests (including doppler scans) and treatments to see if they would be able to help to reduce stillbirths. The UK NSC will evaluate the benefits and risks of each test and treatment against its internationally recognised criteria before making a recommendation on their introduction.</p><p> </p> answering member constituency Ipswich answering member printed Ben Gummer question first answered 17/09/2015 14:50:42 answering member 3988 label Biography information for Ben Gummer
tabling member	4404 label Biography information for Dr Tania Mathias

418704

registered interest
date	14/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Diabetes
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what recent assessment his Department has made of the prevalence of diabetes; and if he will make a statement.
tabling member constituency	Coventry South
tabling member printed	Mr Jim Cunningham
uin	10181
answer	answer is ministerial correction date of answer 17/09/2015 answer text <p>Diagnosed diabetes prevalence is taken from the Quality and Outcomes Framework (QOF) and represents all patients who have been diagnosed with diabetes and included on GP registers.</p><p> </p><p> </p><p> </p><p>Diabetes prevalence is increasing. Diagnosed diabetes prevalence has increased from 2.3 million (5.3%) in 2009/10 to 2.8 million (6.2%) in 2013/14; an increase of nearly half a million people.</p><p> </p><p> </p><p> </p><p>Public Health England’s diabetes prevalence model estimates total diabetes prevalence for England and for all local authorities and clinical commissioning groups (CCG) in England. The model reflects the prevalence of diabetes (diagnosed and undiagnosed) and adjusts for the age, sex, ethnic group and deprivation pattern of the local population.</p><p> </p><p> </p><p> </p><p>The estimated total diabetes prevalence using the diabetes prevalence model is 7.5% in 2014.</p><p> </p><p> </p><p> </p><p>If current trends continue then we estimate that by 2030 there will be over 4 million people with diabetes. This represents 8.8% of the population aged 16 years and over.</p><p> </p><p> </p><p> </p><p>This data is publically available on the Healthier Lives website at:</p><p> </p><p> </p><p> </p><p><a href="http://healthierlives.phe.org.uk/topic/diabetes" target="_blank">http://healthierlives.phe.org.uk/topic/diabetes</a></p><p> </p><p> </p><p> </p><p>The website also provides diagnosed prevalence at the CCG level.</p><p> </p><p> </p><p> </p><p>Tackling diabetes is of great concern to this Government. Building on the National Diabetes Prevention Programme, the Department is developing its plans to improve outcomes for those at risk of and with diabetes. These will be announced in due course.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 10120 question first answered 17/09/2015 15:53:58 answering member 3918 label Biography information for Jane Ellison
tabling member	308 label Biography information for Mr Jim Cunningham

418713

registered interest
date	14/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Nurses: Migrant Workers
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what estimate his Department has made of the number of nurses not born in the EU employed by the NHS in England in each of the last five years.
tabling member constituency	Coventry South
tabling member printed	Mr Jim Cunningham
uin	10121
answer	answer is ministerial correction date of answer 17/09/2015 answer text <p>Information on the country of birth of National Health Service staff is not collected centrally.</p><p> </p> answering member constituency Ipswich answering member printed Ben Gummer question first answered 17/09/2015 15:26:43 answering member 3988 label Biography information for Ben Gummer
tabling member	308 label Biography information for Mr Jim Cunningham

418446

registered interest
date	11/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Eyesight: Testing
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many people were diagnosed with (a) a brain tumour and (b) other conditions as a result of symptoms noticed during examinations by opticians in the last 12 months.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	10017
answer	answer is ministerial correction date of answer 17/09/2015 answer text <p>Information provided by the Health and Social Care Information Centre shows that during 2013/14 there were 159,626 referrals from optometrists to secondary care. It is not possible, however, to identify a diagnosis given the collection of this information is not mandatory.</p><p> </p> answering member constituency North East Bedfordshire answering member printed Alistair Burt question first answered 17/09/2015 10:07:37 answering member 1201 label Biography information for Alistair Burt
tabling member	4131 label Biography information for Jim Shannon

418450

registered interest
date	11/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Dementia
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what criteria NICE has set for new dementia treatments to be recommended for provision by the NHS.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	10022
answer	answer is ministerial correction date of answer 16/09/2015 answer text <p>The National Institute for Health and Care Excellence assesses significant new drugs and treatments, including those for the treatment of dementia, through its technology appraisal programme. Technology appraisals are conducted in accordance with NICE’s <em>Guide to the methods of technology appraisal 2013</em> which is available at:</p><p> </p><p> </p><p> </p><p><a href="http://www.nice.org.uk/article/pmg9/chapter/Foreword" target="_blank">www.nice.org.uk/article/pmg9/chapter/Foreword</a></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 16/09/2015 15:15:57 answering member 4020 label Biography information for George Freeman
tabling member	4131 label Biography information for Jim Shannon

418451

registered interest
date	11/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer Drugs Fund
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the implications for his policies of the decision by NHS England announced on 4 September 2015 to remove (a) the pancreatic cancer drug Abraxane and (b) 22 other drugs and indications from the Cancer Drugs Fund list of approved drugs.
tabling member constituency	Scunthorpe
tabling member printed	Nic Dakin
uin	10091
answer	answer is ministerial correction date of answer 16/09/2015 answer text <p>No such assessment has been made. We remain committed to continuing to invest in the Cancer Drugs Fund which has so far benefitted over 72,000 people with cancer in England.</p><p> </p><p> </p><p> </p><p>We understand that NHS England continues to work with manufacturers seeking to maintain drug and indication combinations within the Fund.</p><p> </p><p><strong> </strong></p><p> </p><p>NHS England has confirmed that patients who are already receiving a drug/indication which is to be removed from the Fund will continue to be treated with that drug until they and their clinicians consider it appropriate to discontinue treatment. In addition, drugs removed from the Fund will continue to be available via Individual Funding Requests if the individual patient meets clinical exceptionality criteria.</p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 16/09/2015 15:22:40 answering member 4020 label Biography information for George Freeman
tabling member	4056 label Biography information for Nic Dakin

418452

registered interest
date	11/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer Drugs Fund
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what mechanisms there are for appeal against NHS England's decision announced on 4 September 2015 to remove (a) Abraxane and (b) 22 other drugs and indications from the Cancer Drugs Fund list of approved drugs; and if he will make a statement.
tabling member constituency	Scunthorpe
tabling member printed	Nic Dakin
uin	10092
answer	answer is ministerial correction date of answer 16/09/2015 answer text <p>NHS England has advised that the mechanisms for appeal are as set out in Appendix G, section 11 of the Cancer Drugs Fund Standard Operating Procedures which are published on NHS England’s website at:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/wp-content/uploads/2013/04/cdf-sop-2015-16.pdf" target="_blank">www.england.nhs.uk/wp-content/uploads/2013/04/cdf-sop-2015-16.pdf</a></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 16/09/2015 15:23:43 answering member 4020 label Biography information for George Freeman
tabling member	4056 label Biography information for Nic Dakin

418453

registered interest
date	11/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer Drugs Fund
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the effect on cancer clinical trials of NHS England's decision announced on 4 September 2015 to remove (a) Abraxane and (b) 22 other drugs and indications from the Cancer Drugs Fund list of approved drugs; and if he will make a statement.
tabling member constituency	Scunthorpe
tabling member printed	Nic Dakin
uin	10093
answer	answer is ministerial correction date of answer 16/09/2015 answer text <p>Neither the Department nor NHS England has made any such assessment.</p><p> </p><p> </p><p> </p><p>Advances in medical science means that new cancer medicines are emerging all the time and NHS England needs to regularly prioritise its national Cancer Drugs Fund (CDF) list so people can access these too. Decisions on which treatments are included on the list are made by the CDF expert clinical panel because it is right these decisions are clinically led.</p><p> </p><p> </p><p> </p><p> </p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 16/09/2015 15:25:30 answering member 4020 label Biography information for George Freeman
tabling member	4056 label Biography information for Nic Dakin

418455

registered interest
date	11/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Prostate Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, when he expects the final results of the National Institute for Health Research's ProtecT trials for prostate cancer testing to be published; and if he will make a statement.
tabling member constituency	East Londonderry
tabling member printed	Mr Gregory Campbell
uin	9996
answer	answer is ministerial correction date of answer 16/09/2015 answer text <p>The ProtecT randomised controlled trial is evaluating the effectiveness, cost-effectiveness and acceptability of active monitoring, radical 3D conformal radiotherapy and radical prostatectomy in men with clinically localised prostate cancer, identified through population-based PSA (Prostate Specific Antigen) testing.</p><p> </p><p> </p><p> </p><p>There have already been over 100 published outputs from ProtecT and these are listed on the National Institute for Health Research (NIHR) website:</p><p> </p><p> </p><p> </p><p>www.nets.nihr.ac.uk/projects/hta/962099</p><p> </p><p> </p><p> </p><p>The researchers plan to publish the primary and most secondary analyses during 2016 at major relevant conferences and in peer-reviewed journals. The primary outcome to be evaluated is definite or probable prostate cancer specific mortality at a median of 10 years following randomisation. A monograph covering these findings is expected to be published in the NIHR Journals Library in July 2017. Findings from longer term follow-up will be published at a later stage.</p><p> </p><p> </p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 16/09/2015 15:17:51 answering member 4020 label Biography information for George Freeman
tabling member	1409 label Biography information for Mr Gregory Campbell